Sorted By Test Name - Mayo Medical Laboratories

BP
88874
1 0.35-0.69 Equivocal
2 0.70-3.49 Positive
3 3.50-17.4 Positive
4 17.5-49.9 Strongly positive
5 50.0-99.9 Strongly positive
6 > or =100 Strongly positive Reference values
apply to all ages.
Clinical References: Homburger HA: Allergic diseases. In Clinical Diagnosis and Management by
Laboratory Methods. 21st edition. Edited by McPherson RA, Pincus MR. WB Saunders, Publ, New York,
Chapter 53, Part VI, pp. 961-971, 2007
Bullous Pemphigoid, BP180 and BP230, IgG Antibodies, Serum
Clinical Information: Bullous pemphigoid (BP) is chronic pruritic blistering disorder found mainly
in aged persons, characterized by the development of tense blisters over an erythematous or urticarial
base. IgG antibasement membrane zone antibodies are found in the serum of patients, and linear IgG and
C3 sediment is found on the basement membrane zone of the lesion. Several well characterized variants
exist including localized, mucous membrane predominant and pemphigoid gestationis, also referred to as
herpes gestationis. Target antigens of the autoantibodies in BP patient serum are BP230 and BP180 also
called BPAG1 and BPAG2. Molecular weight of these antigens is 230 kD and 180 kD, respectively.
BP180 is thought to be the direct target of the autoantibody because of its location along the basement
membranes, and the autoantibody against BP230 is thought to be secondarily produced.
Useful For: Bullous pemphigoid (BP) BP180 and BP230 enzyme-linked immunosorbent assay are
sensitive, objective, and specific tests that should be considered as an initial screening test in the diagnosis
of pemphigoid and its variants. To compare these results with the standard serum test of indirect
immunofluorescence utilizing monkey esophagus substrate.
Interpretation: Antibodies to bullous pemphigoid (BP) BP180 and BP230 have been shown to be
present in most patients with pemphigoid. Adequate sensitivities and specificity for disease are
documented and Mayoâ€s experience demonstrates a very good correlation between BP180 and BP230
results and the presence of pemphigoid (see “Supportive Dataâ€). However, in those patients strongly
suspected to have pemphigoid, either by clinical findings or by routine biopsy, and in whom the
BP180/BP230 assay is negative, follow-up testing by #8052 “Cutaneous Immunofluorescence
Antibodies (IgG), Serum" is recommended. Antibody titer correlates with disease activity in many
patients. Patients with severe disease can usually be expected to have high titers of antibodies to BP.
Titers are expected to decrease with clinical improvement.
Reference Values:
BP180
or =9.0 U (positive)
BP230
or =9.0 U (positive)
Clinical References: 1. Liu Z, Diaz LA, Troy JL: A passive transfer model of the organ-specific
autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal
antigen, BP180. J Clin Invest 1993;92:2480-2488 2. Matsumura K, Amagai M, Nishikawa T, Hashimoto
T: The majority of bullous pemphigoid and herpes gestationes serum samples react with the NC16a
domain of the e180-kD bullous pemphigoid antigen. Arch Dematol Res 1996;288:507-509 3. Stanley JR,
Hawley-Nelson P, Yuspa SH, et al: Characterization of bullous pemphigoid antigen: a unique basement
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 309